|
|
|
Curing metabolic diseases - Denmark a world leader
Denmark leads the world in metabolic disorders research. With Steno Diabetes Center and Hagedorn Research Institute providing a platform for strong basic research in metabolism, and Novo Nordisk supplying 50 percent of the world insulin market and 30 percent of the insulin analogue market, Denmark is considered the strongest diabetes cluster in the world.
For more information visit www.investindk.com
|
|
|
|
|
Cancer research - Denmark a European Frontrunner
Denmark is among the top medical regions in Europe when it comes to academic and commercial cancer research and the country’s cancer research is comparable to Boston and Washington D.C. internationally. Medicon Valley is Europe’s strongest cluster in cancer R&D and no other regions in Europe can match the strong combination of pharmaceutical and biotech company activities in cancer research in Denmark.
For more information visit www.investindk.com
|
|
|
|
|
Preventing inflammatory and infectious
Both within the academic and industrial sectors there are equally strong basic research in inflammatory and infectious diseases,and the Copenhagen based Medicon Valley benefits from easy access to a large pool of experienced researchers working in the field (e.g. from AstraZeneca’s Medicon Valley research center). Besides, several world-class academic research groups ranging from basic immunology to rheumatoid arthritis applied inflammation research are found at the Danish universities and university hospitals.
For more information visit www.investindk.com
|
|
|
|
|
Optimal clinical trials framework
The unique Danish life science environment makes it optimal for companies to execute clinical research in various therapeutic areas. Important parameters such as time, complexity and economy work in favour of companies located here. For more information visit www.investindk.com
|
|
|
|
|
Why Denmark?
When we say Denmark is the best place in the world to do business, it’s not justsomething we claim. We have the facts and figures to prove it: Year after year highly reputed international reports from Forbes, World Bank, Economist Intelligence Unit and others choose Denmark as the best country for business.
For more information visit www.investindk.com
|
|
|
|
|
Area of Biz Excellence...
Looking for world-class R&D competencies within CNS related disorders? Looking for strong corporate research within neuroscience? Looking for partnership with world leading neuroscience companies? Have look at Denmark!
For more information visit www.investindk.com
|
|
|
|
|
The Danish BioTech cluster
As the European leader in drug development, Denmark offers attractive business solutions for foreign biotech companies. This includes R&D collaborations with Danish universities and research organisations establishing European headquarters or entering into a strategic partnership regarding fast development or approval of your product for the European market.
For more information visit www.investindk.com
|
|
|
|
|
Sustaining Innovation in the global biotech industry - Article
As the financial pressures on global biotech's business model intensify, largely due to the scarcity of R&D funding for the vast majority of firms, traditional approaches in the pursuit of innovation are being rethought and reshaped in every corner of the industry...
|
|
|
|
|
Keith Powell Interview
Keith Powell, CEO of Polytherics talks to us about their breakthroughs in the last year, and how payment structures are now changing.
|
|
|
|
|
Kalevi Reijonen Interview
Kalevi Reijonen of FIT Biotech talks about how they are targeting the development of a therapeutic HIV vaccine based on FIT Biotech's proprietary DNA plasmid technology, and how technology impacts on their developments.
|
|
|
|
|
Justyna Baji Interview
Justyna Baji of Bioxcel Corporation tells us a bit about herself, and what makes a good deal.
|
|
|
|
|
Jan de Witt Interview
We caught up with Jan de Witt, MD the Chief Business Officer at Sticares InerACT, a Netherlands-based academic clinical research organization (CRO) to talk about his thoughts on the industry for the next year, and the challenges that are yet to come.
|
|
|
|
|
Strategic partnerships
The key to unlocking value through innovation? Jan de Witt, MD is the Chief Business Officer at Sticares InerACT, a Netherlands-based academic clinical research organization (CRO), operating globally and providing full service for clinical research projects of pharmaceutical and biotechnology companies since 1981. So when it comes to knowing what research is getting funded, and where the investments may be made in the future, there are few in a better position to know...
|
|
|
|
|
Q & A with StevenageCatalyst
Stop, Collaborate & Listen
It might be a the opening lyric from a classic 90s pop/rap anthem, but it also could be the key for smaller biotechs to stave off the funding demon and get the leg-up they need to position themselves a more investable company. To explain more about the concept I spoke to Martino Picardo, CEO at Stevenage Bioscience Catalyst (www.stevenagecatalyst.com), a potentially revolutionary system for up-and-coming biotechs.
|
|
|
|
|
Q3 2010 Review
The following report provides a review of the key deals for Q3, including the therapy areas of metabolism, infectives, hospital health care and oncology. The deals featured in the scorecard for Q3 have a combined value of $13.1 billion.
|
|
|
|
|
Distribution Agreements in Biopharma
The report provides a detailed understand and analysis of how and why companies enter distribution deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
|
|
|
|
|
Manufacturing and Supply Agreements in Biopharma
This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2003 to early 2010.
The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.
|
|
|
|
|
Partnering Agreements with BigPharma
The Partnering Agreements with Bigpharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.
|
|
|
|
|
Co-promotion and Co-marketing Agreements in Biopharma
Co-Promotion and Co-Marketing Agreements
This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2003 to early 2010.
|
|
| Presentations from BioBusiness 2011 |
|
|
Dr. Malcolm Bates, Partner and Head of Life Sciences, Taylor Wessing LLP
Malcolm Bates of Taylor Wessing LLP discusses with Dr Peter Nolan the challenges of licensing in a novel field and the commercial and legal issues including options and rights of first refusal.
|
|
|
|
|
Dr. Peter Nolan, Director and Senior Vice President, Commercial Development, Oxford BioMedica plc
Dr Peter Nolan talks about the licensing of Oxford BioMedica's Lentivector gene delivery technology, the challenges of licensing in a novel field and the commercial and legal issues including options and rights of first refusal.
|
|
|
|
|
Monika Vnuk, Senior Director, Business Development, Pfizer
Monika Vnuk discusses how we can look to emerging economies to drive growth by:- Assessing the landscape of developing markets
- Targeting new disease areas in emerging regions to develop pipelines
- Gaining a foothold in untapped markets by acquiring companies in those areas
|
|
|
|
|
Henrik Ørum, VP & CSO, Santaris Pharma A/S
Henrik joins in our panel discussion about the role of microRNA's and how they can become attractive intervention points for novel human therapeutics.
|
|
|
|
|
Helena Vieira, CEO, BioAlvo
Helen Vieira takes part in our discussion at BioBusiness 2011 about how biotechs can engage more successfully with big pharma.
|
|
|
|
|
Fiona Marston, CEO, Absynth
Fiona Marston of Absynth featured as one of many in our BioBusiness 2011 Innovative Biotech Showcase chaired by One Nucleus, to discuss Absynth Technologies and how Morphosys generates value through early licensing.
|
|
|
|
|
Keith Powell, CEO, Polytherics and Dr. Arvind Hundal, Director of Business Development, Zealand Pharma
Keith Powell of Zealand Pharma featured as one of many in our BioBusiness 2011 Innovative Biotech Showcase chaired by One Nucleus, to discuss the collaboration of Polytherics And Zealand Pharma on novel optimised biopharmaceuticals.
|
|
|
|
|
Dr. Barbara Domayne-Hayman, CEO, Stabilitech
Dr. Barbara Domayne-Hayman of Stabilitech featured as one of many in our BioBusiness 2011 Innovative Biotech Showcase chaired by One Nucleus, to discuss innovative platform technology for stabilisation of vaccines and biopharmaceuticals.
|
|
|
|
|
Dr. Nils P Debus, Office of Technology, Bayer Schering Pharma AG
Dr. Nils P Debus too part in our Pharma Strategy panel: Innovation vs. Cost-Cutting: Who Wins?
|
|
| Presentations from BioBusiness 2010 |
|
|
Gulzar Sandhu and Roger Harrison
Gulzar Sandhu VP of Global Licensing at Bayer Healthcare, and Roger Harrison Chief Business Officer at Algeta talk about a win-win deal around a cancer drug with block-buster potential.
|
|
|
|
|
Ian Massey and Christoph Sarry
Dr Ian Massey Chief Executive Officer at Synosia Therapeutics and Dr Christoph Sarry Global Alliance Director at Roche Pharma Partnering talk about thier partnership in CNS.
|
|
|
|
|
Kees Lucas
Kee Lucas PhD talks about whether there is a shortage of late-stage products driving growth in pre-clinical deals.
|
|
| Current Partnering Reports |
|
|
Co-Promotion & Co-Marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
This report provides details of the latest co-promotion and co-marketing agreements announced in the
pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2005 to mid 2011. The full reports can purchased here.
|
|
|
|
|
Biomarker Partnering Terms and Agreements
The report provides a detailed understanding and analysis of how and why companies enter biomarker
partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an
option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting
with collaborative R&D, and commercialization of outcomes. The full reports can purchased here.
|
|
|
|
|
Companion Diagnostics Partnering Terms and Agreements
Companion diagnostics are an increasingly active component of healthcare business development. In recent years there has been a significant increase in companion diagnostic partnering and M&A activity. The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. This report also provides a comprehensive and detailed review of all companion diagnostic contract agreements announced since 2005.The full reports can purchased here.
|
|
|
|
|
Vaccine Partnering Terms and Agreements
This report provides details of the latest vaccine agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.The full reports can purchased here.
|
|
|
|
|
Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The report provides a detailed understand and analysis of how and why companies enter distribution deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. The full reports can purchased here.
|
|
|
|
|
Drug Delivery Partnering Terms and Agreements in Pharma and Biotech
The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. In recent years many drug delivery companies have evolved into specialty pharma companies, providing a sustainable model to build and grow their businesses. As a result the deals in this report are a mix of development deals with larger pharmaceuticals together with commercialization deals to exploit specialty drug delivery company products. The full reports can purchased here.
|
|
|
|
|
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2003 to early 2010. The full reports can purchased here.
|
|
|
|
|
Partnering and M&A Agreements in Pharma and Biotech Yearbook 2010
The Partnering Agreements in Pharma and Biotech Yearbook 2010 report provides the most comprehensive and in-depth insight into the dealmaking activity of the world’s pharmaceutical and biotechnology companies.The full reports can purchased here.
|
|
|
|
|
Personalized Medicine Partnering Terms and Agreements
This report provides details of the latest personalized medicine agreements announced in the healthcare
sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.The full reports can purchased here.
|
|
|
|
|
Pharmacogenomics Partnering Terms and Agreements
The report provides a detailed understanding and analysis of how and why companies enter
pharmacogenomics partnering deals. The majority of deals are development stage whereby the licensee
obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to
be multicomponent, starting with collaborative R&D, and commercialization of outcomes.The full reports can purchased here.
|
|
|
|
|
Practical Guide to Finding Partners in Pharma & Biotech
Competition for the best technologies and products is higher now than it has ever been. Bigpharma realizes
that in order to prosper, securing the best partnering opportunities is of great importance to the overall future
prospects of the company. Partnering has also become increasingly important for smaller biopharma
companies as they seek to grow development and product portfolios.The full reports can purchased here.
|
|
|
|
|
Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics
The report provides a detailed understanding and analysis of how and why companies enter business,
royalty financing agreements. The focus of the report is on partnerships for royalty assets where partners have entered an agreement to dispose of or acquire said assets. The full reports can purchased here.
|
|